Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2024-05-17 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
北京市中伦（深圳）律师事务所关于灵康药业集团股份有限公司2023年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2023 Annual General Meeting (AGM) of Lingkang Pharmaceutical Group Co., Ltd. It discusses the convening, procedures, qualifications of attendees, and voting results of the AGM. The document does not contain financial statements or detailed financial performance data but focuses on the legality and validity of the AGM process and voting outcomes. The document length is 4139 characters, which is relatively short and consistent with a legal opinion or voting results announcement rather than a full annual report or detailed financial report. The content aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports the official voting results of the AGM.
2024-05-17 Chinese
关于召开“灵康转债”2024年第一次债券持有人会议的通知
Regulatory Filings Classification · 95% confidence The document is a detailed notice about convening the 2024 first convertible bondholders meeting of Lingkang Pharmaceutical Group Co., Ltd. It includes information about the meeting time, place, voting procedures, registration methods, and agenda items related to the convertible bonds. The content focuses on the organization and conduct of a bondholders meeting, including voting on a proposal to terminate an investment project funded by the convertible bond proceeds. There are no financial statements, earnings data, or management discussion of financial results. The document is not an annual report, interim report, earnings release, or audit report. It is not a proxy solicitation for a shareholder meeting but a notice and procedural document for a bondholders meeting. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about a bondholders meeting and voting procedures, not a financial report or a capital/financing update per se. The document length is 4230 characters, which is relatively short and consistent with a meeting notice rather than a full report.
2024-05-16 Chinese
关于终止可转换公司债券募集资金投资项目的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the termination of a convertible bond fundraising investment project. It details the original and new project names, amounts of funds raised and remaining, reasons for termination, and the approval process including board and supervisory committee meetings. The document is focused on the update about the use and termination of funds raised through convertible bonds, including regulatory approvals and compliance with relevant securities regulations. It does not contain financial statements or detailed financial performance data, nor is it a transcript, report, or presentation. It is a formal announcement about a capital/financing update related to the company's fundraising and investment project changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 4335 characters, which is sufficient for a detailed announcement but not a full financial report.
2024-05-16 Chinese
关于召开2024年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2024 first extraordinary general meeting of shareholders for Lingkang Pharmaceutical Group Co., Ltd. It details the meeting date, voting methods, agenda items, registration procedures, and proxy authorization forms. There is no financial data, earnings information, or report content. The document is an announcement informing shareholders about the meeting and voting process, not the actual meeting materials or results. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2024-05-16 Chinese
第四届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Lingkang Pharmaceutical Group Co., Ltd. It details the convening of the fourth board's thirteenth meeting, the attendance, and the voting results on several proposals, including termination of a convertible bond investment project and scheduling of shareholder and bondholder meetings. The document does not contain financial statements or detailed financial data but rather reports on board decisions and meeting outcomes. It also references that detailed content is disclosed elsewhere on the stock exchange website. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The document length is short and focused on board resolutions, not a full report or financial disclosure.
2024-05-16 Chinese
中信证券股份有限公司关于灵康药业集团股份有限公司终止可转换公司债券募集资金投资项目的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion and verification report from CITIC Securities regarding the termination of a convertible bond fundraising investment project by Lingkang Pharmaceutical Group Co., Ltd. It discusses the background of the fundraising, usage of funds, reasons for termination of the investment project, and the approval process by the board and supervisory committee. The document is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a brief announcement or a simple notice. It is a specialized audit or verification report related to the use of raised funds and compliance with regulatory requirements. It does not fit into categories like Capital/Financing Update (CAP) or Regulatory Filings (RNS) because it contains substantive review and opinion on the fundraising project termination. Therefore, the best fit is Audit Report / Information (AR), which covers standalone audit reports and verification opinions related to accounting and regulatory compliance, excluding full annual reports. Q2 2024
2024-05-16 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.